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The eﬀect of a partially hydrolysed formula
based on rice protein in the treatment of
infants with cows milk protein allergy
Guidelines for the dietary management of infants
diagnosed with allergy to cows milk protein
(CMP) recommend substitution of the cows milk
formula by extensively hydrolysed formulas
based on CMP, modiﬁed soy protein formulas
and, in certain cases, amino acid-based formulas.
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Infants diagnosed with allergy to cows milk protein (CMP) are fed
extensively hydrolysed cows milk formulas, modiﬁed soy formulas or
even amino acid-based formulas. Hydrolysed rice protein infant
formulashavebecomeavailableandhavebeenshowntobewelltolerated
by these infants. A prospective open, randomized clinical study to
compare the clinical tolerance of a new hydrolysed rice protein formula
(HRPF) with an extensively hydrolysed CMP formula (EHF) in the
feeding of infants with IgE-mediated cows milk allergy. Ninety-two
infants (46 boys and 46 girls, mean age 4.3 months, range 1.1–
10.1 months) diagnosed with IgE-mediated cows milk allergy were
enrolled in the study. Clinical tolerance to the formula products was
tested. Clinical evaluation included skin prick tests with whole cows
milk, soya and rice as well as antigens of CMP (beta-lactoglobulin,
alpha-lactalbumin, casein and bovine seroalbumin), HRPF and EHF
and speciﬁc IgE determinations to CMP using CAP technology.
Patients were randomized to receive either an EHF based on CMP
or a new HRPF. Follow-up was at 3, 6, 12, 18 and 24 months. Growth
parameters were measured at each visit. One infant showed immediate
allergic reaction to EHF, but no reaction was shown by any infant in
the HRPF group. The number of infants who did not become tolerant
to CMP during the study was not statistically diﬀerent between the two
groups. Measurement of IgE levels of infants allergic to CMP during
the study showed no signiﬁcant diﬀerences between the two formula
groups. Growth parameters were in the normal range and similar
between groups. In this study, the HRPF was well tolerated by infants
with moderate to severe symptoms of IgE-mediated CMP allergy.
Children receiving this formula showed similar growth and develop-
ment of clinical tolerance to those receiving an EHF. In accordance with
current guidelines, this HRPF was tolerated by more than 90% of
children with CMP allergy and therefore could provide an adequate and
safe alternative to CMP-hydrolysed formulas for these infants.
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577Several guidelines have been established for the
treatment of CMP allergy as well as indications
of the nutritional composition of these infant
formulas (1–7).
However, the infant formulas traditionally
used in CMP allergy are not without certain
diﬃculties (8–11). A study carried out in infants
diagnosed with allergy to CMP showed adverse
reactions with a double-blind placebo-controlled
food challenge (DBPCFC) to extensively hydro-
lysed formula (2.2%) and to soy (10%) (12).
Generally, extensively hydrolysed cows milk
formulas have a bitter taste, and this poor
palatability can be a cause of refusal by infants.
Recent publications have recommended that
soy protein formula should not be used during
the ﬁrst 6 months of life for infants with food
allergy (13, 14). These recommendations there-
fore limit the use of soy formulas.
As a result, attention has been given to
providing further options for feeding infants
allergic to CMP, in particular the use of hydro-
lysed formulas based on rice protein supple-
mented with L-lysine and L-threonine to achieve
an amino acid proﬁle similar to that of breast
milk (5, 15).
Studies on hydrolysed rice protein formulas
(HRPF) have focused on their possible use for
feeding infants allergic to CMP. Two studies by
Fiocchi et al. (16, 17) have shown that infants
with allergy to CMP as well as other food
allergies have good tolerance to HRPF.
In spite of the doubts raised by one publication
(18) regarding the nutritional adequacy of hydro-
lysed rice protein formulas, growth was shown to
becorrectinthesestudiesandalsoinotherstudies
carried out using a HRPF for infants diagnosed
with CMP allergy (19, 20).
Furthermore, the nutritional adequacy of such
anewinfantformulawasshowninhealthyinfants
who demonstrated normal growth parameters
when fed a partially hydrolysed rice protein
formula in a double blind, randomized trial (21).
Based on these previous trials, the main
objective of the study was to evaluate the
allergenicity of the HRPF and its eﬃcacy in
feeding infants diagnosed with IgE-mediated
cows milk allergy in comparison with an exten-
sively hydrolysed formula (40% casein and
60%whey).
Secondary objectives were to compare devel-
opment of clinical tolerance to CMP and evalu-
ate growth parameters (weight and length) of the
new HRPF with that of a commercialized exten-
sively hydrolysed formula (40% casein and
60%whey) administered to infants diagnosed
with IgE-mediated cows milk allergy.
Material and methods
Study design and subjects
This was a randomized, open, parallel study of
infants to compare a commercial extensively
hydrolysed infant formula (EHF) with an exper-
imental HRPF. Between September 2004 and
June 2006, 92 healthy term infants were recruited
into the study. Inclusion criteria were appearance
of immediate reactions, mainly urticaria,
erythema and angio-oedema related to the con-
sumption of CMP (at least 2 h previously), the
presence of speciﬁc IgE to cows milk or CMP
(by skin prick test or serum antibodies) and,
unless indicated otherwise, a food challenge test
positive to CMP as per the usual protocol of the
Hospital Department (22, 23). The study was
approved by the Ethics Committee of the La Paz
University Hospital (Madrid, Spain), and written
informed consent was obtained from each
infants parents.
Study formulas
The commercialized EHF, based on extensively
hydrolysed casein (40%) and whey proteins
(60%) derived from cows milk, contained 89%
of the peptides with a molecular weight of less
than 1000 Daltons (EHF). The experimental
formula contained partially hydrolysed rice pro-
tein supplemented with lysine and threonine to
improve the nutritional quality by providing an
amino acid proﬁle similar to breast milk (HRPF).
We deﬁned the control formula as extensively
hydrolysed as it contained most (89%) of the
peptides with a molecular weight of <1000
Daltons, whilst the experimental formula was
deﬁned as partially hydrolysed as it contains a
greater percentage of peptides above 5000 Dal-
tons (8% vs. 2.8%) and only 70% of the peptides
with a molecular weight below 2000 Daltons.
This experimental formula was more hydrolysed
than those partially hydrolysed infant formulas
used for prevention of CMP allergy.
The composition of the formulas complied
with requirements as established by the current
legislation of the European Commission Direc-
tive at the time of starting the study and is shown
in Table 1. The amino acid composition of the
study formulas is shown in Table 2 where it is
compared to the reference values for breast milk
indicated in the Directive 91/321/EEC (15).
The composition of the commercialized EHF
formula was the same throughout the study,
whilst the new HPRF was prepared for ﬁrst-age
feeding (0–6 months, HRPF 1) and as a follow
on formula (as of 6 months of age, HRPF 2).
Reche et al.
578Both study formulas were produced by the
same company (Ordesa Group, S.L., Sant Boi de
Llobregat, Barcelona, Spain). Researchers
advised parents about the introduction of
complementary feeding following established
national guidelines (4). Feeding tolerance and
adverse events were registered throughout the
study period.
Infant characteristics
Ninety-two infants diagnosed with IgE-mediated
cows milk allergy by fulﬁlling the aforemen-
tioned inclusion criteria were eligible for enrol-
ment in the study.
Study
Baseline study assessments. Diagnosis was eval-
uated as suggested by the clinical history: typical
symptoms of immediate allergy; urticaria, angio-
oedema and vomiting appearing before 2 h after
the intake of cows milk formula.
Skin prick tests
Antigens for the skin test. Commercial prepara-
tions (Leti Laboratories, Barcelona, Spain) of
whole cows milk, soya and rice as well as CMP
antigens (beta-lactoglobulin, alpha-lactalbumin,
casein and bovine seroalbumin) were prepared in
the laboratory according to usual techniques to
obtain a ﬁnal solution of 10 mg protein/ml in a
glycerine saline solution. Dilutions of the EHF
and HRPF were prepared for skin prick testing.
Skin test. The skin prick was applied to the
forearm and read after 15 min. Evaluation was
made as per usual criteria (24), i.e. a papule of
3-mm induration compared to a negative control
with saline solution. All infants exceeded this
value of 3 mm.
Biochemical measurements
Serum-speciﬁc IgE for cows milk and its proteins
were measured, alpha-lactalbumin, beta-lacto-
Table 1. Nutritional composition of the study formulas (nutrients per 100 ml
infant formula)
Nutrient Unit/100mls EHF
HRPF first
formula
(0–6 months)
HRPF follow
on formula
(after 6 months)
Protein (g) 1.9 1.7 2.0
Lipids (g) 3.1 3.6 3.1
MCT (g) 0.7 0.6
Carbohydrates (g) 8.3 7.9 8.3
Maltodextrin (g) 8.3 6.3 6.6
Cornstarch (g) – 1.7 1.7
Energy
Kcal 68 71 69
KJ 287 296 290
Vitamin A (mcg) 63.0 63 65
Vitamin D (mcg) 1.1 1.1 1.7
Vitamin E (mg) 1.7 1.7 1.7
Vitamin K (mcg) 5.6 5.6 5.8
Vitamin B1 (mg) 0.7 0.7 0.8
Vitamin B2 (mg) 0.84 0.84 1.28
Vitamin B6 (mg) 1.12 1.12 1.16
Vitamin B12 (mcg) 0.3 0.3 0.3
Vitamin C (mg) 7.0 7.0 7.3
Folic acid (mcg) 5.6 5.6 15
Pantothenic Acid (mg) 0.4 0.4 0.4
Niacin (mg) 0.8 0.8 1.5
Biotin (mcg) 2.1 2.1 2.2
Choline (mg) – 7.1 7.3
Taurine (mg) 5.0 4.9 4.8
L-carnitine (mg) 1.3 1.4 1.5
Inositol (mg) - 3.5 3.6
Calcium (mg) 64.4 63 83
Phosphorus (mg) 36.4 35 51
Magnesium (mg) 5.6 6.3 7.3
Iron (mg) 0.8 1.1 1.1
Zinc (mg) 0.4 0.8 0.9
Copper (mcg) 42.0 42 47
Iodine (mcg) 10.0 11.2 13.1
Sodium (mg) 26.6 32 38
Potassium (mg) 60.2 63 93
Chlorine (mg) 49.0 46 78
Selenium (mcg) 0.9 1.4 1.5
Manganese (mcg) 42.0 46.2 49.6
Relation (Ca/P) 1.8 1.8 1.6
Osmolality 215 mOsm/l 200 mOsm/l 200 mOsm/l
Renal solute load 117 mOsm/l 110 mOsm/l 142 mOsm/l
Nucleotides
Cytidine-5¢-monophosphate
(mg)
– 1.11 1.13
Uridine-5¢-monophosphate
(mg)
– 0.74 0.73
Adenosine-5¢-monophosphate
(mg)
– 0.38 0.38
Guanosine-5¢-monophophate
(mg)
– 0.22 0.22
Inosine-5¢-monophosphate (mg) – 0.22 0.22
EHF, extensively hydrolysed formula; HRPF, hydrolysed rice protein formula.
Table 2. Amino acid content of the study formulas (mg/100 kcal)
Amino acids EHF
HRPF First
formula
HRPF Follow
on formula
Directive
321/1991/EC
Histidine 59.7 45.8 68.4 45
Isoleucine 152.4 80.2 119.8 72
Leucine 252.6 164.2 245.3 156
Lysine 239.3 124.0 162.3 122
Methionine 54.1 45.8 68.4 29
Cystine 29.1 42.0 62.7 24
Phenylalanine 94.5 99.3 148.3 62
Tyrosine 98.1 101.2 151.2 59
Threonine 170.4 81.0 102.7 80
Valine 157.9 89.7 134.0 80
Tryptophan 36.7 30.5 42.9 30
EHF, extensively hydrolysed formula; HRPF, hydrolysed rice protein formula.
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579globulin, casein and bovine seroalbumin, using
the CAP system (Pharmacia Diagnostics), with a
lower cut-oﬀ point of 0.35 kU/l. The level was
above 0.35 kU/l in all infants.
Furthermore, speciﬁc IgE to soy, egg white,
rice and hake (but not the hydrolysed HRPF)
was also measured using the CAP system also
with a cut-oﬀ point of 0.35 kU/l.
Food challenge tests for CMP
Food challenge test for CMP was carried out if
not contraindicated. The reasons for contraindi-
cation of the CMP challenge test were.
1. Symptoms of generalized CMP-related ana-
phylaxis or oedema of the glottis.
2. Episodes of urticaria and/or general angio-
oedema (not exclusively perioral), appearing
within 60 mi after taking CMP, repeated two
or three times, with an interval of less than
3 months since the previous episodes. These
should be accompanied by positive skin prick
tests of more than 3 mm and CMP-speciﬁc
IgE of more than 0.35 kU/l.
3. Other situations which show speciﬁc IgE to
cows milk or proteins of more than 3 kU/l
since the probability of a positive provocation
test is 90% (22)
Seventeen infants were not challenged with
cows milk, because of anaphylaxis or anaphy-
lactic shock, another 38 infants because of
recent generalized urticaria and 33 infants who
showed a value of serum IgE to CMP greater
than 3 kU/l.
A food challenge test for CMP was carried out
in three infants and showed positive.
Initial formula tolerance
Initial tolerance tests to both study formulas
were carried out after recruitment in all children
by giving 120–150 ml of the study products.
Infants tolerant to the study products were
followed up to approximately 24 months of age.
At this initial stage, one infant was withdrawn
from the study as a result of an allergic reaction
to the EHF.
Growth parameters (weight and supine length)
were also evaluated.
Follow-up assessments. Follow-up visits were
carried out at 3 months and at 6 months after
enrolment into the study or at the age of
12 months, then again at 18 and 24 months of
age.
Evaluations
At each visit, the researchers drew up a general
clinical history and evaluated tolerance to the
products. Written instructions were given on the
introduction of complementary foods according
to previously mentioned guidelines, and toler-
ance was checked at subsequent visits.
Growth parameters were measured, as well as
determination of IgE and speciﬁc IgE levels were
measured at each visit.
At the age of 12 months, total IgE levels were
measured as well as speciﬁc IgE to diﬀerent milk
proteins and other foods (egg, ﬁsh, rice and
hake). Tolerance to CMP was determined by the
food challenge test, according to the established
protocol, in the hospital setting with the appro-
priate care facilities.
Food challenge tests
If good clinical tolerance was achieved with
100 ml of cows milk formula during the food
challenge test, the infant was advised to follow an
unrestricted diet according to age and continued
tolerance was conﬁrmed after 2 wk.
If the infant proved tolerant to CMP after the
in-hospital food challenge test, and subsequent
conﬁrmation, participation in the study was
discontinued.
If the infant was still allergic to CMP, follow-
up was continued at 6-month intervals until
approximately 24 months of age.
Statistical analysis
Statistical analysis was carried out using the spss
programme, version 11.5 (SPSS Inc., Chicago,
IL, USA).
The two study groups were compared for
categorical variables such as sex, type of clinical
reaction, family antecedents and the presence of
atopic dermatitis using the chi-square test. Stu-
dents t-test was used for the comparative study
of quantitative variables. Wilcoxons non-para-
metric test was used for any quantitative vari-
ables that did not follow normal distribution,
such as the determination of serum levels of IgE
and speciﬁc IgE.
Diﬀerences were considered statistically signif-
icant when p < 0.05.
Results
Ninety-two infants were recruited (46 boys, 46
girls; mean age 4.3 months range 1.1–
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toms and clinical manifestations are shown in
Tables 3 and 4 respectively. There were no
statistical diﬀerences between the two groups.
Eighty-one infants successfully completed the
study according to the protocol, after conﬁrming
clinical tolerance to the products at the baseline
visit. Five infants in the experimental HRPF
group abandoned follow-up for the following
reasons, two refused to take the study formula,
two for non-attendance at follow-up visits and
one as a result of severe constipation, which was
already present at the start of the study. Six
infants abandoned the study in the EHF group
for the following reasons, two refused to take the
study formula, two for non-attendance at follow-
up visits and one moved to live in another
country. Thus, there were 41 infants in the
HRPF group and 40 in the EHF group at the
end of the study.
With regard to the primary outcome of eval-
uation of the clinical tolerance of the new HRPF,
this was found to be similar when compared to
the standard EHF, as in this EHF group, one
infant showed immediate reaction of urticaria on
face and trunk. However, the diﬀerence in the
clinical tolerance between the groups was not
statistically signiﬁcant.
All infants showed negative results to the
initial skin prick test to rice extract and HRPF.
Speciﬁc determination of IgE to rice also proved
negative.
There was no statistically signiﬁcant diﬀerence
between the number of infants in the two groups
who did not become tolerant to CMP during the
course of the study (Fig. 1). In the EHF group,
21 infants were tolerant to CMP at 12 months,
28 at 18 months and 31 at 24 months. In the
HRPF, 18 were tolerant to CMP at 12 months,
26 at 18 months and 31 at 24 months.
The speciﬁc IgE levels of those children
who remained allergic to CMP at 2 yr of age
are shown in Fig. 2. No statistical signiﬁ-
cant diﬀerences were found between the two
groups.
As mentioned earlier, one infant in the exper-
imental group abandoned the study because of
constipation which was already been present at
recruitment. All other infants showed good
digestive tolerance to the study formulas (ab-
sence of vomiting and other digestive symptoms).
Table 3. Baseline characteristics of the study population
Parameter EHF HRPF p
Gender (M/F) 25/21 21/25 ns
Age in months 4.2 (1.5 – 8.8) 4.4 (1.1 – 10.1) ns
Appearance first symptom
First bottle cows milk
formula (CMF)
23 23 ns
After 1 wk of CMF 18 19 ns
Between 1 and 3 wk of CMF 5 4 ns
Quantity of cows milk
formula causing reaction
Hardly any 2 0 ns
Less than 30 (ml) 17 18 ns
Between 30 and 90 (ml) 22 15 ns
More than 90 (ml) 5 13 ns
Repeated episodes 24 20 ns
EHF, extensively hydrolysed formula; HRPF, hydrolysed rice protein formula.
Table 4. Clinical symptoms at enrolment in the study.
Symptom N 
Generalised urticaria 23
Urticaria of face and neck 20
Vomiting 11
Anaphylaxis 15
Anaphylactic shock 4
Perioral erythema 8
Others 11
Fig. 1. Number of infants allergic to CMP over time. EHF,
Extensively hydrolysed formula; HRPF, Hydrolysed rice
protein formula. p = Not signiﬁcant (NS).
Fig. 2. Cows milk protein (CMP)-Speciﬁc IgE (who did not
become tolerant to CMP). EHF, Extensively hydrolysed
formula; HRPF, Hydrolysed rice protein formula. p = Not
signiﬁcant (NS).
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according to the WHO Child Growth Standards
(25) and are shown in Figs 3, 4 and 5. There were
no statistical diﬀerences between the groups.
Discussion
The main objective of the study was to compare
the clinical tolerance of the HRPF and its eﬃcacy
in feeding infants diagnosed with CMP allergy
with an EHF. One infant in the EHF group was
clinically intolerant to the product as shown by
an immediate reaction. However, this is within
the acceptable limit that 90% of cows milk
allergic patients will not react to the product with
95% conﬁdence (1–4, 6). No infant demonstrated
allergenicity to the experimental formula. The
results of the tests for initial allergenicity were
not statistically diﬀerent between the two groups
studied.
The number of infants still allergic to CMP
during the course of the study was similar in
both groups, conﬁrming the adequacy of the
new formula when compared to the commercial
EHF.
The speciﬁc IgE in both groups was markedly
raised by 18 months. This may be because of the
fact that those who became tolerant to CMP at
12 months of age were excluded from further
follow-up.
Previous studies have indicated the low aller-
genicity of a HRPF. In an animal model, 7-to
12-day old guinea pigs were fed a hydrolysed rice
formula, a conventional cows milk formula or
water. A challenge was given after a sensitization
period (26). When challenged with the same
proteins, the group receiving the cows milk
formula showed signiﬁcantly more reactions than
the group receiving the hydrolysed HRPF. In
addition, when this group was challenged with
the HRPF, there was no reaction and only 2
(4.4%) showed mild reactions after challenge
with rice protein.
Studies in infants allergic to CMP fed with
hydrolysed HRPF have shown good tolerance.
In a small study, 18 infants allergic both to CMP
and soy received a hydrolysed rice formula. Skin
prick tests showed positive in eight children for
rice and two for rice hydrolysate. Positive serol-
ogy for rice using the CAP system technology
was found in seven infants. DBPCFC (double-
blind placebo-controlled food challenge) with
hydrolysed rice formula was negative (16) indi-
cating clinical tolerance and therefore suggesting
rice hydrolysate may be used as a protein source
in children with multiple food-induced reactions.
A more recent study by the same group
assessed tolerance to a HRPF in children allergic
to CMP (17). Allergy work-up involved skin
prick tests with whole milk, a-lactalbumin,
b-lactoglobulin and total caseins as well as
speciﬁc IgE determinations (CAP technology)
to whole milk. Sensitization to rice and rice
hydrolysate formula was measured. The speciﬁc
IgE was evaluated together with immunoblotting
to CMP, to rice and hydrolysed rice formula.
Fig. 3. Weight for age z-scores. EHF, Extensively hydro-
lysed formula. HRPF, hydrolysed rice protein formula.
p = not signiﬁcant (NS).
Fig. 5. Weight for height z-scores. EHF, Extensively hy-
drolysed formula; HRPF, hydrolysed rice protein formula.
p = not signiﬁcant (NS).
Fig. 4. Height for age z-scores. EHF, Extensively hydroly-
sed formula; HRPF, hydrolysed rice protein formula.
p = not signiﬁcant (NS).
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for rice and 4/91 hydrolysed rice infant formula.
Immunoblotting was positive to rice proteins for
70/96 infants. Response was weakly positive to
hydrolysed rice infant formula in 6/96. The
DBPCFC was negative to hydrolysed rice protein
formula in all cases. This suggests that hydrolysis
reduces antigenicity of rice protein by abolishing
IgE-binding capacity.
These studies are relevant to our study as they
provide further data on the clinical tolerance to
hydrolysed rice protein formulas in children with
immediate reactions to CMP.
In this study, the HRPF was generally well
tolerated, with the exception of two infants who
refused the product after receiving another
product over a weekend. One of the main
complaints given by parents is that infants reject
hydrolysed formulas because of an unpleasant
taste. A recent double-blind study to evaluate the
palatability of diﬀerent formulas used to feed
infants with CMP allergy showed that the soy
formulas and HRPF had the best taste scores
followed by diﬀerent hydrolysed formulas (27).
Good oral tolerance because of its pleasant
odour, taste and ﬂavour was found with the
HRPF in healthy infants (21).
The good palatability of the new formula
oﬀers an alternative in the older infant used to
breast milk feeding when there is a need to switch
to a hypoallergenic formula.
Other further studies have documented the
good tolerance of the hydrolysed rice protein
formula (16, 17, 19, 28).
The capacity for a partially hydrolysed rice
protein formula to sustain normal growth was
shown in healthy infants when consumed for the
ﬁrst 4 months after birth (21). In this study,
comparison was made with a group of infants
receiving a standard commercial formula.
Two studies evaluated the nutritional value of
a rice hydrolysate in infants diagnosed with
CMP. They showed similar growth to those
receiving a soy formula in early life (19) and
during the weaning period of 6–12 months (20).
This was contradicted in a study by Savino et al.
(18) who found that growth was impaired in
children with atopic dermatitis and CMP who
received a rice hydrolysate formula compared to
another formula. In these studies quoted, the
same hydrolysed rice protein formula was admin-
istered to the allergic infants.
In this study, growth of the infants receiving
the HRPF was within normal parameters for
both weight and height when compared to the
WHO Growth Standards. There was no statisti-
cal diﬀerence between the groups in growth.
No biochemical markers of plasma amino acid
levels were measured during the study.
One ﬁnal point for consideration is the recent
concern, raised by the Food Standards Agency of
the United Kingdom, regarding the question of
arsenic levels in rice drinks, especially the content
of inorganic arsenic that is considered as more
harmful (29). There are no EU regulations on the
contents of arsenic in food.
In the United Kingdom, there is a general limit
of 1 mg/kg (or 1 ppm) for arsenic in food.
The study carried out by the Food Safety
Authority (FSA) on the arsenic content of rice
drinks found an average concentration of
0.023 mg/kg (0.023 ppm) of total arsenic and
0.012 mg/kg (0.012 ppm) of inorganic arsenic.
The arsenic content of the hydrolysed rice
infant formula administered in this study has
been analysed. The total arsenic content of the
reconstituted product is 6.4 times less than the
values quoted in the FSA study, and the inorganic
arsenic is more than six times lower than the
values found in the FSA study.
The European Food Safety Authority (EFSA)
has recently published a Scientiﬁc Opinion on
Arsenic in Food (30). The recommendation of
the Panel was that so as to reﬁne risk assessment
of inorganic arsenic, there is a need to produce
speciation data for diﬀerent food commodities to
support dietary exposure and dose–response data
for the possible health eﬀects.
In this EFSA report, the total arsenic content
of rice-based infant food was found to be
0.158 mg/kg of dry product. The hydrolysed rice
protein formula in our study contained six times
less than this value.
Furthermore, EFSA assumed that 70% of
total arsenic is inorganic so that the concentra-
tion of inorganic arsenic in rice-based infant food
was 0.110 mg/kg. The inorganic arsenic content
of the study formula contains 7.3 times less than
this value.
In summary, in this study, the HRPF was well
tolerated by infants with moderate to severe
symptoms of IgE-mediated CMP allergy. Chil-
drenreceivingthisformulashowedsimilargrowth
and development of clinical tolerance to those
receiving an EHF. In accordance with current
guidelines, this HRPF was tolerated by more than
90% of children with CMP allergy and therefore
could provide an adequate and safe alternative to
CMP-hydrolysed formulas for these infants.
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